Principal Financial Group Inc. trimmed its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 0.3% during the fourth quarter ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the ...

Insulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category. Insulet faces significant business and financial risks ...

Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Insulet (PODD – Research Report) today and set a price target of $293.00.

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong demand and adoption of ...

Investors eyeing a purchase of Insulet Corp (Symbol: PODD) shares, but tentative about paying the going market price of $286.60/share, might benefit from considering selling puts among the ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?